GlassScriptPhysician profile
Dylan K Barnett
NPI 1073075735
$2,300.98
in general payments reported to CMS, 2019-2025
23 companies · $981 in 2025
The $981 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.65 · 2022: $129 · 2023: $555 · 2024: $562 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $560.84 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $302.17 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $295.14 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $179.25 | 2023-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.57 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $143.73 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.71 | 2023-2025 | Xifaxan |
| Lundbeck LLC | $83.14 | 2025 | Rexulti |
| Pfizer INC. | $81.45 | 2023-2025 | |
| Astellas Pharma US INC | $63.46 | 2023-2024 | Veozah, Myrbetriq |
| Seqirus USA INC | $54.91 | 2025 | Flucelvax, Fluad |
| Medtronic, INC. | $40.54 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Bayer Healthcare Pharmaceuticals INC. | $36.25 | 2022-2025 | |
| Tris Pharma INC | $34.89 | 2025 | Dyanavel Xr |
| Genzyme Corporation | $24.37 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.00 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $19.44 | 2024 | Dificid |
| Aimmune Therapeutics, INC. | $16.12 | 2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $15.50 | 2023 | Eliquis |
| Eisai INC. | $15.28 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.03 | 2022 | |
| Idorsia Pharmaceuticals US INC | $11.73 | 2022 | |
| Corium, LLC | $9.46 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Barnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.